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CVD 103-HgR is a liveoral cholera vaccinethat, in phase I and II studies to date, has been well
tolerated and immunogenic. In challenge studies of US volunteers conducted 4-5 weeks after
vaccination, CVD 103-HgR provided significantprotection against experimental cholera due to
classical and EI Tor Vibrio cholerae 01. To determine the onset and duration of protection, two
volunteer challenge studies were conducted: the first, 6 months after vaccination and the second,
8 days after vaccination. In both studies, CVD 103-HgR was 100% protective against diarrhea
and significantly reduced the rate of shedding of vibriosafter challenge with V.cholerae classical
Inaba strain 569B, the virulent parent strain of CVD 103-HgR. Previously vaccinated subjects
were less likely than naive controls to develop rises in titer of vibriocidal antibodies after chal-
lenge (P = .002), and the mean peak titer of vibriocidalantibodies was less than among controls.
CVD 103-HgR can provide homologous protective immunity as soon as 8 days after vaccination
and protection can persist for at least 6 months.
The expansion of the seventh pandemic of cholera into
South America has increased the urgency to develop a safe,
effective, and long-lasting cholera vaccine. A vaccine that is
rapidly effective after a single dose and that could be given
orally would be especially desirable because of the ease of
administration to residents of remote areas and its usefulness
soon after cholera is introduced into a community.
CVD I03-HgR is a live oral Vibrio cholerae 0 I vaccine
strain that meets these criteria. The strain was developed by
deleting 94% of the ctxA gene and introducing a gene encod-
ing resistance to mercury into a chromosomal locus (hlyA) of
V. cholerae classical Inaba strain 569B [l]. In phase I and II
studies in North American, European, Thai, and Peruvian
adults and Indonesian and Peruvian children, this vaccine
has been well tolerated and in those without preexisting vib-
riocidal antibodies, highly immunogenic [2-4] (unpublished
data). In volunteer challenge studies of North Americans
conducted 4-5 weeks after vaccination, CVD I03-HgR pro-
tected against experimental challenge with both El Tor and
classical biotypes of V. cholerae 0 I [2]. The interval of 4-5
weeks between vaccination and challenge was chosen on the
basis of the likely timing of mature immune responses and
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practical expedience in maintaining a cohort of vaccinees
willing to undergo challenge. Moreover, this was the interval
used in previous studies that demonstrated the effectiveness
of infection-derived and vaccine-derived immunity to chol-
era [2, 5-8].
We wished to further explore the limits ofprotective immu-
nity elicited by CVD I03-HgR in terms of how soon after
vaccination protective responses appear and how long these
responses persist. These issues are especially important be-
cause a vaccine with rapid onset of protection (i.e., within
days ofvaccination) would be an extremely valuable tool for
the control of epidemic cholera as soon as an outbreak is
detected. In addition, a vaccine that elicits protective re-
sponses of long duration would be desirable for control of
endemic cholera. Finally, a medium-range duration of pro-
tection (e.g., months) would be desirable in a vaccine for use
by travelers. We report the results of volunteer challenge
studies conducted in two cohorts of adult volunteers vacci-
nated with CVD I03-HgR 8 days or 6 months before homolo-
gous V. cholerae challenge to approximate the expected level
of protective efficacy in the field soon after vaccination and
within the subsequent 6 months.
Materials and Methods
Volunteers. Healthy adults 18-39 years old from the Balti-
more community were recruited to participate in a 6-month or
an 8-day postvaccination challenge study. Volunteers were
screened to confirm their good health by medical histories and
physical examinations, a battery of clinical hematologic and
chemistry tests, electrocardiograms,and serologictests for syphi-
lis. hepatitis B surface antigen, and human immunodeficiency
virus. Before vaccination and challenge, stools were examined
for bacterial pathogens, ova, and parasites.
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Vaccine. V. cholerae vaccine strain CVD 103-HgR was
grown, lyophilized, and packaged at the Swiss Serum and Vac-
cine Institute. The formulation consisted of sachets containing a
single dose (3-5 X 108 or 3-5 X 109 viable organisms) oflyophi-
lized vaccine and 25 mg of aspartame. An accompanying sachet
contained an effervescent buffer powder consisting of 2.5 g of
sodium bicarbonate and 1.65 g of ascorbic acid. The vaccine
was stored at 4°C before use.
Vaccination. Two cohorts of volunteers were recruited for
the two challenge studies depending on the time of challenge
after vaccination. In the first study, 22 outpatient volunteers
received a single oral dose of r-- 3-5 X 108 cfu ofCVD 103-HgR;
2 months later 7 other volunteers received a single oral dose of
,...., 3-5 X 109 cfu. These volunteers were to be challenged 6 and
4 months after vaccination, respectively, in the same challenge
study. The higher dose of vaccine was chosen because prelimi-
nary data suggested increased immunogenicity after this dose
among vaccinees residing in an endemic area (unpublished
data). In the second study, 11 volunteers received 3-5 X 108 cfu
8 days before challenge.
At the time of vaccination, a sachet of buffer was added to
100 mL of distilled water in a cup. A sachet containing a dose of
vaccine was then added to the buffer to make a vaccine cocktail,
which the volunteers ingested. Volunteers had nothing to eat or
drink for 90 min before and after vaccination.
Diarrhea after vaccination was defined as passage of at least
four unformed stools over 24 h. Volunteers kept a stool record
for 5 days after vaccination and called the Center for Vaccine
Development daily for 5 days to report symptoms.
Challenge. In the first study, volunteers vaccinated with 108
cfu ofCVD 103-HgR 6 months previously (n = II) and volun-
teers vaccinated with 109 cfu 4 months previously (n = 3) were
admitted to the Research Isolation Ward of the Center for Vac-
cine Development (University of Maryland Hospital) with a
group of unvaccinated control volunteers (n = 15). Challenge
studies were done under quarantine administered by the Bureau
ofDisease Control, Baltimore City Health Department. After 48
h of acclimatization, volunteers received a dose of4 X 106 cfu of
V. choleraestrain 569B. In the second study, volunteers who had
received 108 cfu ofCVD 103-HgR 8 days before challenge were
admitted to the Research Isolation Ward, were observed for 48
h, and received 3 X 107 cfu of V. cholerae strain 569B.
Volunteers in both studies were closely monitored for 10 days
after challenge; vital signs were measured every 6 h. All stools
from each volunteer were collected in plastic containers, exam-
ined, and graded on a five-point scale [I], and the volume was
measured when the stool was loose. Volunteers were inter-
viewed daily by a physician and asked about symptoms. Diar-
rhea after challenge was defined as two or more loose stools
within 48 h totaling ~200 mL in volume or a single loose stool
~300 mL in volume. Antibiotic therapy (tetracycline, 500 mg
every 6 h for 5 days) was given before discharge.
Bacteriology. Every stool passed by volunteers after chal-
lenge was cultured daily for the challenge strain. Stool was
plated directly onto thiosulfate-citrate-bile-sucrose (TCBS) agar
and into alkaline peptone water enrichment broth for overnight
incubation before plating onto TCBS agar. The number ofchal-
lenge organisms per gram of stool was determined each day for
up to two stools.
At --20 and 44 h after challenge, fasting volunteers swal-
lowed gelatin capsules containing string devices (Entero-Test:
HDC, Mountain View, CA) to collect samples of bile-stained
duodenal fluid. After 4 h, the strings were removed and the
color and pH of the distal 15 em were recorded. Duodenal fluid
was squeezed from the end of the string and cultured as de-
scribed.
Immunology. For volunteers who would receive a challenge
4-6 months after vaccination, serum samples were obtained be-
fore vaccination and on days 10 and 28 after vaccination and
just before challenge. For those who would receive the challenge
8 days after vaccination, serum was obtained before vaccination
and just before challenge. After challenge, serum was obtained
at days 7, 21, and 28. Titers of vibriocidal antibodies were mea-
sured in serum [9] and antibody responses to V. cholerae lipo-
polysaccharide and cholera toxin were measured by ELISA [10].
Results
Study 1: Vaccination and Challenge 4-6 Months Later
Clinical responses to vaccination. No diarrhea or other sig-
nificant symptoms were reported after vaccination.
Serologic responses to vaccination. After vaccination with
a single oral dose of 108 cfu ofCVD 103-HgR, 20 (95%) of
21 vaccinees developed fourfold or greater rises in serum
Inaba vibriocidal antibody with a geometric mean peak titer
after vaccination of 3561. After vaccination with a single
dose of 109 cfu, all 7 vaccinees developed rises in vibriocidal
antibodies with a peak geometric mean titer of 2826 after
vaccination. Among all 28 vaccinees, 19 (68%) had peak
vibriocidal reciprocal titers ~2560. After vaccination, 13
(62%) of21 vaccinees who received the lower dose and all 7
who received the higher dose developed significant rises in
serum IgG antibody against cholera toxin.
Clinical and bacteriologic responses to challenge. Of the
28 volunteers who had been vaccinated 4-6 months previ-
ously, 14 (11 who had received 108 cfu and 3 who had re-
ceived 109 cfu) were available for challenge. After challenge
with V. cholerae classical Inaba strain 569B, 10 (67%) of I 5
control volunteers and none of 14 previously vaccinated vol-
unteers developed diarrhea (P < .001, Fisher's exact test).
The mean stool volumes, number of loose stools, and mean
incubation period are shown in table I. All 15 control volun-
teers and 3 (21 %)of 14 vaccinees shed the challenge strain in
the stool (P < .00 I, Fisher's exact test); the mean number of
organisms shed by vaccinees with positive coprocultures was
10-fold less than that shed by control volunteers (table I).
Serologic responses to challenge. Before challenge, vac-
cinees had a significantly higher Inaba vibriocidal antibody
titer than did controls (table 2); after challenge, the vibrioci-
dal titer rose in only half the vaccinees while all controls had
significant rises in vibriocidal antibody titers (P = .002,
Fisher's exact test). The peak geometric mean reciprocal titer
in vaccinees after challenge (1640) was significantly less
than in controls (9778).
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Table 1. Clinical and bacteriologic responses to classical Inaba Vibrio cholerae challenge in recipi-
ents of a single dose of CVD I03-HgR given 6 months or 8 days before challenge.
Time of
immunization No.
before No. with Volume (mL) Incubation shedding Peak
challenge. diarrheal No. (mean) of of stools period in excretion
group. P total loose stools* (mean. range) (mean h) stool/total (mean cfu/g)
4-6 months
Vaccinees 0/14 0 0 3/14 1.6 X 103 t
Controls 10115 6.3 753 (227-2741) 55.9 15/15 1.5 X 104
P <.001+ <.001+ NS'
8 days
Vaccinees 0/11 0 0 I1II 2.0 X 103
Controls 8/11 7.8 1059 (214-2810) 36.6 9/11 3.5 X 104
P <.001+ <.002+ NS'
NOTE. NS, not significant; cfu, colony-forming units. Vaccine efficacy was 100%.
* During 8-day observation.
t Three vaccinees with positive coprocultures,
+Fisher's exact test.
, t test.
Study 2: Vaccination and Challenge 8 Days Later
Clinical response to vaccination. No diarrhea or signifi-
cant symptoms were reported by volunteers after vaccina-
tion. No vaccine organisms were detected in the stools of
volunteers immediately before challenge.
Clinical and bacteriologic response to challenge. After
challenge with V. cholerae classical Inaba strain 569B, 8
(73%) of 11 control volunteers and none of 11 previously
vaccinated volunteers developed diarrhea (P < .001, Fisher's
exact test). The mean stool volumes, number ofloose stools,
and mean incubation period are shown in table 1. Nine
(82%) of 11 control volunteers and only I (9%) of 11 vacci-
nees shed the challenge strain in the stool (P = .002, Fisher's
exact test); the number of organisms shed by the vaccinee
was 10-fold less than that shed by control volunteers
(table I).
Serologic response to challenge. The serologic response to
challenge is shown in table 3. The vaccinees had a mean
reciprocal vibriocidal titer of 682 and the controls had a
mean titer of 14 on the day ofchallenge. The vibriocidal titer
peaked earlier among vaccinees (day 7 after challenge) than
among controls (day 22) and fell more rapidly after chal-
lenge (table 3).
Discussion
The ideal cholera vaccine should have the following char-
acteristics: safety, oral delivery for ease of administration,
Table 2. Immune responses in volunteers vaccinated with a single oral dose ofCVD 103-HgR and
challenged 4-6 months later with Vibrio cholerae classical Inaba strain 569B.
Vaccinees Controls
No. with Peak No. with Peak
responses Response response responses Response response
after before after after before after
challenge* challenge challenge challenge* challenge challenge
Inaba vibriocidal antibody (GMT)+ 7/14t 276+ 1640' 15/15 t 66+ 9778 1
Inaba LPS IgG antibody (GMT) 7/14 69 305 5/15 76 168
Cholera toxin IgG antibody (00) 6/14 0.37 0.99 15/15 0.11 1.36
NOTE. GMT. geometric mean titer; LPS, lipopolysaccharide; 00, optical density. Of 14 challenged vacci-
nees, I I had received 5 X 108 cfu and 3.had received 5 X 109 cfu of CVD 103-HgR.
* Fourfold rise in antibody titer or significant change in 00 after vaccination.
t Vaccinees vs. controls: P = .002. Fisher's exact test.
+Vaccinees vs. controls: P = .007. Mann-Whitney U test.
1 Vaccinees vs. controls: P = .004. Mann-Whitney U test.
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Table 3. Immune responsesin volunteers vaccinatedwith a singleoral doseofCVD 103-HgRand
challenged 8 days later with Vibrio cholerae classical Inaba strain 569B.
Challenge day
Vaccination.
-8 days 0 7 22 28
Vaccinees
Vibriocidal antibody (GMT) 15 682 2119 597 422
Inaba LPS IgG (GMT) 22 23 35 35 29
Cholera toxin IgG (OD) 0.18 0.46 0.73 0.59 0.61
Controls
Vibriocidal antibody (GMT) NA 14 1280 1940 854
Inaba LPS IgG (GMT) NA 29 55 92 80
Cholera toxin IgG (OD) NA 0.07 0.37 1.10 1.03
NOTE. GMT. geometric mean titer; OD. optical density; LPS. lipopolysaccharide; NA. not applicable.
requirement for only a single dose, high protective efficacy, a
long duration of protection, and a rapid onset of protection
after vaccination. In volunteer challenge studies to date,
CVD 103-HgR has met these criteria. The maximum dura-
tion ofprotection elicited by CVD 103-HgR is unknown, but
the hope is that CVD 103-HgR will perform like other live
attenuated vaccines in providing many years of protective
efficacy.
In these volunteer studies, the challenge strain chosen
(classical Inaba strain 569B) was the virulent parent strain of
CVD 103-HgR. Clearly, the choice of the biotype-homolo-
gous strain for challenge increased the likelihood of showing
protection by CVD 103-HgR. In two previous challenge stud-
ies in which CVD 103-HgR vaccinees received challenges
with biotype-heterologous EI Tor Inaba or EI Tor Ogawa,
---65% protective efficacy was seen 4-5 weeks after vaccina-
tion [2] (unpublished data). The onset and duration of bio-
type heterologous protection will be determined in future
field efficacy trials.
These studies also confirmed an important serologic ob-
servation originally made in phase II studies among residents
of developing areas. In Thai soldiers, overall seroconversion
rates to CVD I03-HgR were lower than in US and European
volunteers, in large part because Thais had elevated, some-
times high, vibriocidal titers before vaccination [4]. In our
cohort of US volunteers vaccinated 6 months before chal-
lenge, many of whom retained elevated vibriocidal titers at
the time of challenge, the rate of seroconversion after chal-
lenge was half that seen in naive control volunteers (P =
.002). Vibriocidal antibody may be an epidemiologic corre-
late of immunity [11-13], but rates of seroconversion after
vaccination among populations with high levels of preexist-
ing vibriocidal antibody may not correlate with or predict
vaccine efficacy [4]. In other words, failure to manifest sero-
conversion of vibriocidal antibody after vaccination with
CVD 103-HgR in persons who already have elevated titers
before vaccination does not signify lack ofimmunogenicity.
To the contrary, it appears that individuals with immunity
evidenced by elevated serum vibriocidal titers often are not
further boosted after vaccination with CVD 103-HgR or ex-
posure to wild-type V. cholerae 0 I.
We conclude that the cholera vaccine CVD 103-HgR is
likely to be successful for control of epidemic cholera and
cholera among travelers because of its rapid onset of protec-
tion. Its usefulness in endemic areas will be measured in up-
coming field studies.
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